#Mexico #Mexico City #financial report #Genomma Lab #EBITDA margin

Genomma Lab Internacional Reports Financial Results for 2025

On February 25, 2026, Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) shared its financial results for the fourth quarter and the entire year of 2025. The report details key financial metrics and offers insights from CEO Marco Sparvieri, shedding light on the challenges and resilience of the company amid a fluctuating market conditions.

Highlights from the Report

Sales Performance

In 2025, Genomma faced a decline in like-for-like sales of -4.3%, largely due to a weaker summer beverage season in Mexico and a general slowdown in consumer spending. The Q4 results were particularly notable, with like-for-like sales plummeting by -12.9%. Sparvieri noted that this steep decline was a strategic decision to reduce sell-in volumes to retailers, aiming to normalize excess stocks after two disappointing seasons in the OTC and beverage segments.

Despite the hit on sales, the sell-out figures for Q4 showed only a moderate decline of -2.2%, suggesting that overall consumer demand remains strong. This resilience points to a potential recovery as market conditions stabilize.

Financial Metrics

The financial summary for Q4 2025 indicates total net sales of 4,017 million Mexican pesos, reflecting a decrease of -13.9% compared to the previous year. Overall for 2025, net sales were recorded at 17,541 million pesos, down -5.7%. In contrast, gross profit margins did reflect solid performance, although they dipped slightly to 61.0% in Q4 from 63.1% in Q4 2024.

Genomma's EBITDA margin reached a robust 23.4% for the full year, indicating effective management and productivity improvements, even amidst decreasing sales. The fourth quarter EBITDA margin was 22.1%, showing the company’s ability to partially offset operational pressures through reduced selling, general and administrative expenses (SGA).

Net Income Analysis

The net income for continuous operations suffered a significant decrease of -23.1% in 2025, even though the company benefitted from a lower net interest expense. The prior-year figures impacted current performance, particularly due to substantial non-cash foreign exchange losses stemming from the depreciation of the Argentine peso, which dropped by 42% during the reporting period.

Strategic Initiatives

Sparvieri emphasized proactive measures the company has taken, including unlocking MXN 1.1 billion in productivity savings to bolster investments in growth areas such as product innovation, expansion of distribution channels, enhanced in-store execution, and stronger marketing communication strategies. This indicates a forward-looking approach that seeks to reignite growth despite short-term challenges.

Looking Ahead

As Genomma Lab heads into 2026, the management anticipates continued operational expenses may be higher and sales may reflect softness initially. However, they are optimistic that the growth initiatives will start yielding results, particularly in the latter half of the year, thereby enhancing operational leverage. The management views the downturn in 2025 as cyclic, rather than structural.

Analyst Coverage

The company is currently covered by eight sell-side analysts from various reputable brokerages, reflecting confidence in Genomma's market position and future prospects.

Conclusion

In conclusion, while 2025 posed several challenges for Genomma Lab Internacional, its ability to maintain a healthy EBITDA margin and strategic focus on cost control and innovation demonstrates a commitment to long-term growth. Moving forward, the company appears poised to navigate through the current economic climate successfully and emerge stronger in the coming years.